Dear Editor,
A meta-analysis done by Guo1 that was published in Tobacco Induced Diseases, reported a pooled odds ratio of 2.20, concluding that active smoking is significantly associated with the risk of severe COVID-19. Another current meta-analysis reported greater odds of COVID-19 progression among smokers compared to never smokers2. Most of the studies in these meta-analyses were from China and focused only on cigarette smoking1,2. Here, we describe characteristics of tobacco use among 193 confirmed COVID-19 patients who were interviewed during their hospitalization from 15 March to 15 April 2020, in the Imam-Khomeini Hospital of Ardabil University of Medical Sciences (ArUMS) in Iran. The protocol was approved by the Institutional Review Board of Ardabil University of Medical Sciences (Approval ID: IR.ARUMS.REC.1399.044) and verbal informed consent was obtained from the patients.
All patients tested positive for SARS-CoV-2 by nasopharyngeal swabs using real-time reverse-transcription-polymerase-chain-reaction (rRT-PCR) assay; they were at least 18 years old and willing to participate in an approximately 5-min interview. Interviews were administrated in the first two days of hospitalization to collect information regarding demographics, COVID-19-associated symptoms, and use of tobacco products including waterpipe (WP, hookah), cigarettes, and e-cigarettes.
As shown in Table 1, 15 (7.8%) and 14 (7.3%) of the patients reported current (past-month) WP or cigarette use, respectively. No patients were dual WP/cigarette or e-cigarette users. Of the 14 cigarette smokers, 2 had cardiovascular disease (CVD), 1 chronic respiratory illness, 1 diabetes, 2 other conditions (e.g. kidney illness or rheumatoid arthritis), and 4 reported having >1 chronic condition. Among 15 WP smokers, 3 reported having CVD, 1 other condition, and 2 having >1 chronic condition. The average time between the onset of symptoms and hospitalization was approximately 4 days for WP smokers, 3 days for cigarette smokers, and 5 days for never-smokers. More than half (n=8) of cigarette smokers and 40% (n=6) of WP smokers reported their COVID-19 symptoms as severe compared to 22% (n=36) of never-smokers.
Table 1
Characteristics | Never-smokers a (N=164) | Waterpipesmokers b (N=15) | Cigarette smokers c (N=14) | p | Total (N=193) |
---|---|---|---|---|---|
n (%) /mean±SD | n (%) / mean±SD | n (%) /mean±SD | n (%) /mean±SD | ||
Age (years) | 52.2±14.8 | 52.5±11.8 | 58.2±16.5 | 0.344 | 52.6±14.8 |
Gender | |||||
Male | 95 (57.9) | 15 (100.0) | 13 (92.9) | 0.001 | 123 (63.7) |
Female | 69 (42.1) | 0 (0.00) | 1 (7.1) | 70 (36.3) | |
Education | |||||
Illiterate | 25 (15.2) | 2 (13.3) | 3 (21.4) | 0.697 | 30 (15.5) |
≤High school | 111 (67.7) | 11 (73.3) | 7 (50.0) | 129 (66.8) | |
Academic | 28 (17.1) | 2 (13.3) | 4 (28.6) | 34 (17.6) | |
History of chronic diseases | |||||
None | 91 (55.5) | 9 (60.0) | 4 (28.6) | 0.482 | 104 (53.9) |
CVD | 24 (14.6) | 3 (20.0) | 2 (14.3) | 29 (15.0) | |
Pulmonary | 7 (4.3) | 0 (0.0) | 1 (7.1) | 8 (4.1) | |
Diabetes | 11 (6.7) | 0 (0.0) | 1 (7.1) | 12 (6.2) | |
Other | 13 (7.9) | 1 (6.7) | 2 (14.3) | 16 (8.3) | |
>1 condition | 18 (11.0) | 2 (13.3) | 4 (28.6) | 24 (12.4) | |
Days between symptoms onset and | 5.0±2.0 | 4.0±1.3 | 3.1±1.0 | 4.8±1.9 | |
hospitalization | |||||
Symptoms (yes vs no) | |||||
Dry cough | 138 (84.1) | 11 (73.3) | 13 (92.9) | 0.353 | 162 (83.9) |
Fever | 108 (65.9) | 10 (66.7) | 11 (78.6) | 0.625 | 129 (66.8) |
Body pain | 81 (49.4) | 12 (80.0) | 5 (35.7) | 0.038 | 98 (50.8) |
Shortness of breath | 90 (54.9) | 3 (20.0) | 8 (57.1) | 0.033 | 101 (52.3) |
How do you define your symptoms | |||||
Mild | 51 (31.3) | 4 (26.7) | 1 (7.1) | 0.030 | 56 (29.2) |
Moderate | 76 (46.6) | 5 (33.3) | 5 (35.7) | 88 (44.8) | |
Severe | 36 (22.1) | 6 (40.0) | 8 (57.1) | 50 (26.0) | |
Cigarette smoking frequency/month | |||||
<10 | – | – | 3 (21.4) | – | 3 (21.4) |
10–20 | – | – | 7 (50.0) | 7 (50.0) | |
>20 | – | – | 4 (28.6) | 4 (28.6) | |
WP smoking pattern | |||||
Daily/weekly | – | 8 (53.3) | – | – | 8 (53.3) |
Monthly | – | 7 (46.7) | – | 7 (46.7) | |
Outcome of diseased | |||||
Discharged in <5 days | 102 (62.2) | 11 (73.3) | 9 (64.3) | 0.002 | 122 (63.2) |
Transferred to ICU | 60 (36.6) | 1 (6.7) | 5 (35.7) | 66 (34.2) | |
Died | 2 (1.2) | 3 (20.0) | 0 (0.0) | 5 (2.6) |
In line with a previous report3, the most common COVID-19 symptoms were fever and dry cough, which did not differ significantly between smokers (cigarettes or WP) and never-smokers. However, shortness of breath was reported more frequently by cigarette smokers compared to never-smokers and WP smokers. Body pain was reported more frequently among WP smokers compared to cigarette smokers and never-smokers.
Three out of the five deaths occurred among WP smokers with the remaining two deaths among never-smokers. When interviewed at the beginning of the study, all three WP smokers and 2 never-smokers who later died due to COVID-19 infection reported having chronic conditions.
It is suggested that WP smoking be regulated to restrict COVID-19 transmission4,5 and several countries accordingly have temporarily shut down WP cafes4,6. Berlin et al.7 highlighted that ‘lockdown may be an opportune moment to quit to reduce not only the smoker’s health risk but also that of his/her family members’. This recommendation might not be practical, however, in countries like Iran (the epicenter of COVID-19 in the Middle East), where WP smoking is culturally rooted, highly prevalent, and frequently occurs at home8,9. As social distancing restrictions are relaxed, it is critical to provide guidelines (e.g. best cleaning practices, hygiene standards) and increase awareness regarding the risks of sharing WP. Future studies investigating the association between smoking and COVID-19 should consider WP smoking as a potential conduit of infection for this new disease. These studies could answer critical questions about whether smoking WP in a café environment will increase the risk of contracting coronavirus, how café owners must sanitize WP components to reduce the risk of virus transmission, and whether sharing the same WP hose in a home environment between family members or friends increases the risk of suffering from serious symptoms due to COVID-19 illness.
The limitations of this study include the self-report of underlying medical conditions, tobacco smoking, and the severity of COVID-19-associated symptoms. Despite these limitations, this descriptive study is among the first to describe the patterns of WP use among COVID-19 patients. Our findings highlight the need for larger scale studies to further investigate the influence of smoking behavior on the severity and the prognosis of COVID-19.